Journal of global infectious diseases · 2026
Examining the Clinical Efficacy of Novel Beta-Lactam and Beta-Lactamase Inhibitor Antibiotics: A Systematic Review and Meta-Analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elkholi Mohamed Hamed, Shoaib Mohamed Ibrahim, Alrais Zeyad, Hassan Khalid Omar
Аннотация
INTRODUCTION: This study evaluated the efficacy of novel β-lactam/β-lactamase (NβL/βLIs) combination against Enterobacteriaceae and Pseudomonas aeruginosa infections.
METHODS: We searched CENTRAL, MEDLINE, Embase, CINAHL, Google Scholar, and clinical trial registries through April 20, 2025, and included randomized controlled trials (RCTs) comparing NβL/βLIs with best available therapy (BAT). Pediatric, noncomparative, and in vitro studies were excluded. We performed meta-analyses using random effects models to calculate odds ratios (OR) with 95% confidence intervals (CIs), summarized using GRADE methodology. We included 22 RCTs with 11,238 participants. All RCTs except one were conducted worldwide between 2012 and 2025. Approximately 52% of participants used novel β-lactamase inhibitors. Risk of bias (RoB) was assessed using the RoB 2 tool.
RESULTS: NβL/βLIs were as effective as BAT (OR 1.12, 95% CI 0.95-1.31; I 2 = 29%; 21 studies, 7630 participants). In multidrug resistance (MDR) infections, NβL/βLIs showed a trend toward benefit (OR 1.23, 95% CI 0.95-1.58; I² =12%; 17 RCTs, 1713 participants). For microbiological cure, NβL/βLIs were superior (OR 1.33, 95% CI 1.06-1.66; I 2 = 68%; 22 studies), mainly due to improved efficacy in complicated tract infections. Safety outcomes were comparable between groups.
CONCLUSIONS: Novel βL/-βLIs are as effective as BAT in treating Enterobacteriaceae and P. aeruginosa infections, including MDR strains.
METHODS: We searched CENTRAL, MEDLINE, Embase, CINAHL, Google Scholar, and clinical trial registries through April 20, 2025, and included randomized controlled trials (RCTs) comparing NβL/βLIs with best available therapy (BAT). Pediatric, noncomparative, and in vitro studies were excluded. We performed meta-analyses using random effects models to calculate odds ratios (OR) with 95% confidence intervals (CIs), summarized using GRADE methodology. We included 22 RCTs with 11,238 participants. All RCTs except one were conducted worldwide between 2012 and 2025. Approximately 52% of participants used novel β-lactamase inhibitors. Risk of bias (RoB) was assessed using the RoB 2 tool.
RESULTS: NβL/βLIs were as effective as BAT (OR 1.12, 95% CI 0.95-1.31; I 2 = 29%; 21 studies, 7630 participants). In multidrug resistance (MDR) infections, NβL/βLIs showed a trend toward benefit (OR 1.23, 95% CI 0.95-1.58; I² =12%; 17 RCTs, 1713 participants). For microbiological cure, NβL/βLIs were superior (OR 1.33, 95% CI 1.06-1.66; I 2 = 68%; 22 studies), mainly due to improved efficacy in complicated tract infections. Safety outcomes were comparable between groups.
CONCLUSIONS: Novel βL/-βLIs are as effective as BAT in treating Enterobacteriaceae and P. aeruginosa infections, including MDR strains.